| Project/Area Number |
20890300
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (Start-up)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | National Institute of Biomedical Innovation |
|---|
Principal Investigator |
ABE Yasuhiro National Institute of Biomedical Innovation, 創薬基盤研究部バイオ創薬プロジェクト, 研究員 (20509898)
|
|---|
| Research Collaborator |
角田 慎一
鎌田 春彦
井上 雅己
山根 美紀
長野 一也
野村 鉄也
萱室 裕之
河原 倫之
有田 修平
古屋 剛
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥3,302,000 (Direct Cost: ¥2,540,000、Indirect Cost: ¥762,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,742,000 (Direct Cost: ¥1,340,000、Indirect Cost: ¥402,000)
|
|---|
| Keywords | 蛋白質 / 自己免疫疾患 / アンタゴニスト / ファージ表面提示法 / バイオコンジュゲーション |
|---|
| Research Abstract |
Blocking the binding of TNF to TNF receptor subtype 1 (TNFR1) is believed to be a promising strategy for the treatment of autoimmune disease. Recently, we generated the TNFR1-selective mutant TNF with antagonistic activity (R1antTNF) using phage display technique. In this study, the anti-inflammatory effects of R1antTNF have been investigated. First, to improve the in vivo stability, polyethylene glycol-modified R1antTNF (PEG-R1antTNF) was prepared. In the autoimmune disease model, the clinical score of the mice given PEG-R1antTNF was improved. These results suggest that selective blocking of TNFR1 by PEG-R1antTNF could be an effective therapeutic strategy against autoimmune disease.
|
